Proceeds to fund advancement of the company’s lead TRBV9 program through clinical proof-of-concept study in axial spondyloarthritis and progression of broader pipeline Company’s approach selectively targets and depletes pathogenic immune cells with the potential to reset the immune…

VANCOUVER, BC, March 25, 2025 /PRNewswire/ – Trilogy Metals Inc. (TSX: TMQ) (NYSE American: TMQ) (“Trilogy Metals”, “Trilogy” or “the Company”) is providing an update on the Ambler Access Project (the “Ambler Road”) – the proposed 211-mile, industrial-use-only road from the Upper Kobuk…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.